Differential regulation of TROP2 release by PKC isoforms through vesicles and ADAM17
Tim M Wanger1, Sharon Dewitt1, Anne Collins2
1College of Biomedical and Life Sciences, Cardiff University, Dental School, Cardiff CF14 4XY, United Kingdom.
Abstract:
TROP2, a cancer cell surface protein with both pro-oncogenic and anti-oncogenic properties is cleaved by ADAM17. ADAM17 dependent cleavage requires novel PKC activity which is blocked by the ADAM10/ADAM17 inhibitor GW64 as well as by the PKC inhibitor Bim-1. Full length TROP2 release is induced by classical PKC activation and blocked by Gö6979, without affecting ADAM17 dependent TROP2 cleavage. Full length TROP2 is released in ectosomes, as inhibition of endocytosis did not prevent release. Inhibition of the atypical PKC isoform PKCζ stimulated metalloproteinase dependent N-terminal alternative TROP2 cleavage. The resulting alternative TROP2 cleavage product remains membrane associated via a disulphide bond, but is released in microvesicles with an average size of 107nm. Inhibition of endocytosis following PKCζ inhibition prevented alternative cleavage and release of TROP2, suggesting that these events require endocytic uptake and exosomal release of the corresponding microvesicles. The alternative TROP2 cleavage product was also found in PC3 cell lysates following deglycosylation, and may represent a novel biomarker in prostate cancer.
Insights
Tumor protein TROP2 cleavage by ADAM17 is PKC-dependent. Alternative TROP2 cleavage by PKCζ, independent of endocytosis, may yield a novel prostate cancer biomarker.
Area of Science:
- Molecular Biology
- Cancer Research
- Cell Biology
Background:
- TROP2 is a cell surface glycoprotein implicated in cancer progression.
- ADAM17 is a metalloproteinase involved in shedding cell surface proteins.
- Protein kinase C (PKC) isoforms regulate various cellular processes, including protein cleavage.
Purpose of the Study:
- To investigate the mechanisms regulating TROP2 cleavage by ADAM17.
- To identify the role of PKC isoforms in TROP2 processing.
- To explore the potential of TROP2 cleavage products as cancer biomarkers.
Main Methods:
- Inhibition of ADAM17 and PKC isoforms using specific chemical inhibitors (GW64, Bim-1, Gö6979).
- Analysis of TROP2 cleavage products and their release mechanisms (ectosomes, microvesicles).
- Investigation of the role of endocytosis in TROP2 processing.
Main Results:
- ADAM17-dependent TROP2 cleavage requires novel PKC activity.
- Full-length TROP2 is released in ectosomes upon classical PKC activation.
- PKCζ inhibition stimulates alternative TROP2 cleavage, releasing a microvesicular product dependent on endocytosis.
Conclusions:
- TROP2 processing is regulated by distinct PKC isoforms and metalloproteinases.
- Alternative TROP2 cleavage products released via microvesicles may serve as novel biomarkers, particularly in prostate cancer.
- Understanding TROP2 cleavage pathways offers insights into cancer biology and potential therapeutic targets.
Related Concept Videos
Overview of Secretory Vesicles
Various proteins regulate the aggregation of molecules inside the secretory vesicles. Chromogranins...
Rab Proteins
Rab proteins switch between a cytosolic, GDP-bound inactive state and a membrane-anchored, GTP-bound active state. By themselves, Rabs show slow rates of GDP/GTP exchange and GTP hydrolysis. Thus, Rab proteins are considered...
Vesicular Tubular Clusters
With the help of motor proteins such...
GPCRs Regulate Adenylyl Cylase Activity
Regulation of Nuclear Protein Sorting
Coat Assembly and GTPases
Coat assembly depends on the local availability of phosphatidylinositol phosphates or PIPs and GTP-binding proteins. Adaptor proteins, which link the coat proteins to the membrane, bind to these PIPs and play a crucial role in controlling...


